Poster presentations of Vaccibody’s two lead candidates: 6M interim clinical data on VB10.16, and preclinical data on VB10.NEO alone and in combination with bempegaldesleukin (NKTR-214)
Oslo, Norway, February 27th, 2019 – Vaccibody AS today announced that clinical and preclinical data will be presented at the upcoming 2019 American Association for Cancer Research (AACR) Annual Meeting, which will be held from March 29- April 3, 2019 in Atlanta, Georgia. The abstracts will be published in advance of the AACR Annual meeting at the AACR Online Itinerary Planner: https://www.abstractsonline.com/pp8/#!/6812.
“We are excited that four separate abstracts presenting Vaccibody’s pipeline have been accepted for poster presentation at this year’s AACR Annual Meeting,” said Agnete Fredriksen, PhD, President and CSO of Vaccibody. Two of the abstracts cover Vaccibody’s two lead candidates VB10.16 and VB10.NEO and are presenting the 6M interim data and the clinical design, respectively. In addition, two abstracts present preclinical data for VB10.NEO that demonstrates the progress we have made characterizing the unique Vaccibody platform and its ability to induce strong tumor protective immune responses alone and in combination with bempegaldesleukin (NKTR-214).
Details of the four poster presentations are as follows:
Abstract #CT209
Title: Safety, efficacy and immunogenicity of VB10.16, a therapeutic DNA vaccine targeting human papillomavirus (HPV) 16 E6 and E7 proteins for high grade cervical intraepithelial neoplasia (CIN 2/3): 6-month data from an exploratory open-label phase I/2a trial
Session Date and Time: Tuesday Apr 2, 2019 1:00 PM – 5:00 PM local time
Abstract #CT217
Title: An open-label, Phase I/IIa study of VB10.NEO (DIRECT-01) in combination with checkpoint blockade in patients with locally advanced or metastatic solid tumors including melanoma, NSCLC, renal cell carcinoma, urothelial cancer or SSCHN
Session Date and Time: Tuesday Apr 2, 2019 1:00 PM – 5:00 PM local time
Abstract #5033
Title: “Vaccibody DNA vaccine platform VB10.NEO induces strong neo-antigen specific CD8+ T cell responses critical to cure established tumors in pre-clinical models”
Session Data and Time: Wednesday Apr 3, 2019 8:00 AM – 12:00 PM local time
Abstract #2256
Title: “Combination of neoantigen DNA plasmid vaccine VB10.NEO and NKTR-214, a CD122-biased immunostimulatory cytokine, induces strong neoantigen-specific T cell responses and sustained tumor regression in pre-clinical models”
Session Data and Time: Monday Apr 1, 2019 1:00 PM – 5:00 PM local time
About VB10.16
VB10.16 is an investigational therapeutic DNA vaccine developed to treat human papillomavirus type 16 (HPV16) induced pre-malignancies and malignancies. The drug candidate has demonstrated favorable 6M interim clinical data in a Phase I/IIa study in pre-cancerous HPV16 induced high grade cervical intraepithelial neoplasia (HSIL; CIN 2/3).
About VB10.NEO
VB10.NEO, is a proprietary therapeutic DNA vaccine which uses the patient’s own neoantigens for the personalized treatment of cancer patients. A phase I/IIa neoantigen clinical trial is currently enrolling patients with locally advanced or metastatic melanoma, non-small cell lung carcinoma, clear renal cell carcinoma as well as urothelial cancer or squamous cell carcinoma of the head and neck.
About Vaccibody
Vaccibody is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies. The company is a leader in the rapidly developing field of individualized cancer neoantigen vaccines and is using the Vaccibody technology to generate best-in-class therapeutics to treat cancers with a high unmet medical need. A phase I/IIa neoantigen clinical trial is currently enrolling patients with locally advanced or metastatic melanoma, non-small cell lung carcinoma, clear renal cell carcinoma as well as urothelial or squamous cell carcinoma of the head and neck. Vaccibody’s front runner program (VB10.16) is a therapeutic DNA vaccine against HPV16 induced pre-malignancies and malignancies. The first-in-human study (phase I/IIa), which has reported positive 6M interim data, evaluates the safety and immunogenicity of VB10.16 in women with high grade cervical intraepithelial neoplasia (HSIL; CIN 2/3). www.vaccibody.com
Contact:
CEO Martin Bonde, PhD
Vaccibody AS
Cell: +45 2025 3560
mbonde@vaccibody.com
